281 related articles for article (PubMed ID: 29649812)
1. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
2. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
3. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
4. Safety of hymenoptera venom immunotherapy: a systematic review.
Incorvaia C; Frati F; Dell'Albani I; Robino A; Cattaneo E; Mauro M; David M; Qualizza R; Pastorello E
Expert Opin Pharmacother; 2011 Nov; 12(16):2527-32. PubMed ID: 21883032
[TBL] [Abstract][Full Text] [Related]
5. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
6. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
[TBL] [Abstract][Full Text] [Related]
8. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
9. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
10. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
11. A modified ultrarush insect venom immunotherapy protocol for children.
Steiss JO; Jödicke B; Lindemann H
Allergy Asthma Proc; 2006; 27(2):148-50. PubMed ID: 16724635
[TBL] [Abstract][Full Text] [Related]
12. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
[TBL] [Abstract][Full Text] [Related]
13. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy.
Kochuyt AM; Stevens EA
Clin Exp Allergy; 1994 Jan; 24(1):35-41. PubMed ID: 8156444
[TBL] [Abstract][Full Text] [Related]
15. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
17. Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence.
Cavallucci E; Ramondo S; Renzetti A; Turi MC; Di Claudio F; Braga M; Incorvaia C; Schiavone C; Ballone E; Di Gioacchino M
J Investig Allergol Clin Immunol; 2010; 20(1):63-8. PubMed ID: 20232775
[TBL] [Abstract][Full Text] [Related]
18. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
19. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
20. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
